{'fraction_non_alphanumeric': 0.036511156186612576, 'fraction_numerical': 0.02738336713995943, 'mean_word_length': 5.9020979020979025, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hepatic HMGCoA reductase in human cholelithiasis: effects of chenodeoxycholic and ursodeoxycholic acids*

Abstract. To study further the role of hepatic cholesterol synthesis in patients with gallstones, the activity of the rate‐limiting step in cholesterbgenesis, hydroxy‐methyl glutaryl co‐enzyme A reductase (HMGCoAR), was measured in operative wedge liver biopsies from ten patients with untreated cholesterol gallstones, six with pigment stones and ten controls. Hepatic HMGCoAR was also measured in six patients with cholesterol‐rich gallstones treated for 1–24 months with 14‐6‐18‐6 mg chenodeoxycholic acid (CDCA) kg‐1 day‐1, in two patients with radiolucent pigment stones treated with 17‐3 and 17‐7 mg CDCA kg‐1 day‐1 and in ten other patients with cholesterol‐rich stones given 4–5‐7‐2 mg ursodeoxycholic acid kg‐1 day‐1 for 1–6 months. HMGCoAR activity was also related to the free and esterified cholesterol content of both hepatic homogenates and the microsomal fractions.